Voyager Therapeutics (VYGR) News Today $3.91 -0.17 (-4.17%) Closing price 03/3/2025 04:00 PM EasternExtended Trading$4.03 +0.12 (+3.07%) As of 03/3/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Voyager reports promising data for early stage trial in Alzheimer’s disease treatmentMarch 3 at 6:44 PM | msn.comVoyager Therapeutics announces data from SAD trial of VY7523March 3 at 6:44 PM | markets.businessinsider.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRMarch 3 at 2:40 PM | prnewswire.comVoyager Therapeutics' (VYGR) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Voyager Therapeutics in a report on Monday.March 3 at 11:45 AM | marketbeat.comVoyager Therapeutics Reports Positive Topline Data for VY7523 in Alzheimer’s Disease TrialsMarch 3 at 7:17 AM | quiverquant.comVoyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's DiseaseMarch 3 at 7:00 AM | globenewswire.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Average Rating of "Buy" from BrokeragesMarch 2 at 2:31 AM | americanbankingnews.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Given Consensus Rating of "Buy" by BrokeragesShares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) have been assigned a consensus rating of "Buy" from the nine brokerages that are covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation and one has given a stroMarch 2 at 2:29 AM | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRFebruary 25, 2025 | prnewswire.comVoyager Therapeutics to Present at Multiple Upcoming Investor ConferencesFebruary 25, 2025 | globenewswire.comVOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. ...February 24, 2025 | gurufocus.comVOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the FirmFebruary 24, 2025 | globenewswire.comVYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law FirmFebruary 21, 2025 | prnewswire.comVYGR Investors Have Opportunity to Join Voyager Therapeutics, Inc. Fraud Investigation with the Schall Law FirmFebruary 20, 2025 | businesswire.comKirby McInerney LLP Announces Investigation Against Voyager Therapeutics, Inc. (VYGR) on Behalf of InvestorsFebruary 19, 2025 | globenewswire.comVoyager Therapeutics (VYGR) to Release Earnings on WednesdayVoyager Therapeutics (NASDAQ:VYGR) will be releasing earnings before the market opens on Wednesday, February 26.February 19, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGRFebruary 18, 2025 | prnewswire.comResearch Analysts Set Expectations for VYGR FY2025 EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Stock analysts at Wedbush reduced their FY2025 earnings per share (EPS) estimates for shares of Voyager Therapeutics in a report issued on Tuesday, February 11th. Wedbush analyst Y. Zhong now forecasts that the company will earn ($1.12) perFebruary 15, 2025 | marketbeat.comWhat is Wedbush's Estimate for VYGR FY2029 Earnings?Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for Voyager Therapeutics in a report issued on Tuesday, February 11th. Wedbush analyst Y. Zhong anticipates that the company will post earnings of ($0.86February 13, 2025 | marketbeat.comVoyager Therapeutics' chief scientific officer sells shares worth $24,087February 12, 2025 | msn.comVoyager Therapeutics COO Robin Swartz sells $30,927 in stockFebruary 12, 2025 | msn.comVoyager Therapeutics' chief legal officer sells $19,393 in stockFebruary 12, 2025 | msn.comVoyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | uk.finance.yahoo.comVoyager Therapeutics price target lowered to $12 from $14 at Wells FargoFebruary 12, 2025 | markets.businessinsider.comVoyager Therapeutics stock hits 52-week low at $4.12February 12, 2025 | msn.comWedbush Reaffirms Outperform Rating for Voyager Therapeutics (NASDAQ:VYGR)Wedbush reaffirmed an "outperform" rating and issued a $9.00 price objective (down from $11.00) on shares of Voyager Therapeutics in a research note on Tuesday.February 11, 2025 | marketbeat.comVoyager Therapeutics stock tumbles after IND application delayedFebruary 11, 2025 | msn.comVoyager Therapeutics to Assess 'Alternative Payloads' for ALS Gene Therapy ProgramFebruary 11, 2025 | marketwatch.comVoyager Therapeutics shifts focus for ALS therapyFebruary 11, 2025 | msn.comVoyager to assess alternate payloads for SOD1 ALS gene therapy programFebruary 11, 2025 | markets.businessinsider.comVoyager Provides Update on SOD1 ALS Gene Therapy ProgramFebruary 11, 2025 | globenewswire.comVoyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences ConferenceFebruary 6, 2025 | markets.businessinsider.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of "Buy" from AnalystsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) has been given a consensus recommendation of "Buy" by the nine ratings firms that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy recommendation and one has issuedFebruary 5, 2025 | marketbeat.comVoyager: Crossing The Blood-Brain Barrier, Competitors, And Investment RelevanceJanuary 30, 2025 | seekingalpha.comPositive Outlook for Voyager Therapeutics Driven by Promising CNS Gene Therapies and Innovative TRACER PlatformJanuary 27, 2025 | markets.businessinsider.comVoyager Therapeutics (NASDAQ:VYGR) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday.January 27, 2025 | marketbeat.comWhat is Leerink Partnrs' Forecast for VYGR Q1 Earnings?Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Analysts at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Voyager Therapeutics in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst L. Nsongo expects that the compaJanuary 24, 2025 | marketbeat.comEquities Analysts Issue Forecasts for VYGR FY2025 EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Voyager Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will earn ($2.20) perJanuary 22, 2025 | marketbeat.comInsider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells 3,087 Shares of StockJanuary 16, 2025 | insidertrades.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells $15,712.83 in StockVoyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) COO Robin Swartz sold 3,087 shares of the stock in a transaction dated Tuesday, January 14th. The stock was sold at an average price of $5.09, for a total value of $15,712.83. Following the sale, the chief operating officer now owns 109,241 shares of the company's stock, valued at $556,036.69. This represents a 2.75 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.January 15, 2025 | marketbeat.comOppenheimer Sticks to Its Buy Rating for Voyager Therapeutics (VYGR)January 15, 2025 | markets.businessinsider.comCantor Fitzgerald Weighs in on VYGR FY2024 EarningsVoyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Voyager Therapeutics in a note issued to investors on Monday, January 13th. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company wiJanuary 14, 2025 | marketbeat.comCantor Fitzgerald Initiates Coverage of Voyager Therapeutics (VYGR) with Overweight RecommendationJanuary 11, 2025 | msn.comVoyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Cantor FitzgeraldCantor Fitzgerald assumed coverage on Voyager Therapeutics in a research report on Friday. They issued an "overweight" rating for the company.January 10, 2025 | marketbeat.comJane Street Group LLC Lowers Stock Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)Jane Street Group LLC trimmed its holdings in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 56.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 84,652 shares of the company's stock after selling 108,141 shares during the period. JaneJanuary 6, 2025 | marketbeat.comVoyager Therapeutics, Inc. (NASDAQ:VYGR) Shares Sold by State Street CorpState Street Corp trimmed its holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) by 50.1% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 892,743 shares of the company's stock after selling 896,446 shares duDecember 30, 2024 | marketbeat.comVoyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | msn.comVoyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.comInsider Selling: Voyager Therapeutics, Inc. (NASDAQ:VYGR) COO Sells 6,500 Shares of StockDecember 27, 2024 | insidertrades.comRobin Swartz Sells 6,500 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) StockVoyager Therapeutics, Inc. (NASDAQ:VYGR - Get Free Report) COO Robin Swartz sold 6,500 shares of the business's stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now directly owns 112,328 shares of the company's stock, valued at $634,653.20. The trade was a 5.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.December 26, 2024 | marketbeat.com Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address VYGR Media Mentions By Week VYGR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VYGR News Sentiment▼0.200.70▲Average Medical News Sentiment VYGR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VYGR Articles This Week▼125▲VYGR Articles Average Week Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Day One Biopharmaceuticals News Rocket Pharmaceuticals News Pharvaris News Avid Bioservices News Cogent Biosciences News Oculis News Opthea News Prothena News Maravai LifeSciences News Cronos Group News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VYGR) was last updated on 3/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredLeaked Trump video exposes his secret stocksTen investments secretly owned by Trump’s biggest backers. Ten investments intrinsically tied to the polici...Porter & Company | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYGR Stock Alerts